DE60212814D1 - Liposomen-targeting von matrix-metalloproteinase-hemmern - Google Patents

Liposomen-targeting von matrix-metalloproteinase-hemmern

Info

Publication number
DE60212814D1
DE60212814D1 DE60212814T DE60212814T DE60212814D1 DE 60212814 D1 DE60212814 D1 DE 60212814D1 DE 60212814 T DE60212814 T DE 60212814T DE 60212814 T DE60212814 T DE 60212814T DE 60212814 D1 DE60212814 D1 DE 60212814D1
Authority
DE
Germany
Prior art keywords
matrix metal
liposomes
proteinase inhibitors
metal proteinase
tumor cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60212814T
Other languages
English (en)
Other versions
DE60212814T2 (de
Inventor
Medina Oula Penate
Erkki Koivunen
Paavo Kinnunen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CTT Cancer Targeting Technologies Oy
Original Assignee
CTT Cancer Targeting Technologies Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by CTT Cancer Targeting Technologies Oy filed Critical CTT Cancer Targeting Technologies Oy
Application granted granted Critical
Publication of DE60212814D1 publication Critical patent/DE60212814D1/de
Publication of DE60212814T2 publication Critical patent/DE60212814T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1217—Dispersions, suspensions, colloids, emulsions, e.g. perfluorinated emulsion, sols
    • A61K51/1234—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/1282—Devices used in vivo and carrying the radioactive therapeutic or diagnostic agent, therapeutic or in vivo diagnostic kits, stents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Nanotechnology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Oncology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE60212814T 2001-03-26 2002-03-26 Liposomen-targeting von matrix-metalloproteinase-hemmern Expired - Fee Related DE60212814T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20010620A FI113840B (fi) 2001-03-26 2001-03-26 Matriisi-metalloproteinaasi-inhibiittorien käyttö liposomien kohdentamisessa
FI20010620 2001-03-26
PCT/FI2002/000252 WO2002076491A1 (en) 2001-03-26 2002-03-26 Liposome targeting of matrix metalloproteinase inhibitors

Publications (2)

Publication Number Publication Date
DE60212814D1 true DE60212814D1 (de) 2006-08-10
DE60212814T2 DE60212814T2 (de) 2007-02-08

Family

ID=8560842

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60212814T Expired - Fee Related DE60212814T2 (de) 2001-03-26 2002-03-26 Liposomen-targeting von matrix-metalloproteinase-hemmern

Country Status (23)

Country Link
US (2) US20040213833A1 (de)
EP (1) EP1372694B1 (de)
JP (1) JP2004529127A (de)
KR (1) KR20040000414A (de)
CN (1) CN1250279C (de)
AT (1) ATE331526T1 (de)
BR (1) BR0208681A (de)
CA (1) CA2441227A1 (de)
CZ (1) CZ20032805A3 (de)
DE (1) DE60212814T2 (de)
DK (1) DK1372694T3 (de)
EE (1) EE200300467A (de)
ES (1) ES2266458T3 (de)
FI (1) FI113840B (de)
HU (1) HUP0303649A3 (de)
IL (1) IL158114A0 (de)
NO (1) NO20034280L (de)
NZ (1) NZ528043A (de)
PL (1) PL365248A1 (de)
RU (1) RU2003131332A (de)
SK (1) SK12982003A3 (de)
WO (1) WO2002076491A1 (de)
YU (1) YU74703A (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7279150B2 (en) 2002-01-24 2007-10-09 Barnes-Jewish Hospital Chelating agents with lipophilic carriers
IL152609A0 (en) * 2002-11-03 2003-06-24 Hapto Biotech Inc Liposomal compositions comprising haptotactic peptides and uses thereof
CN1314704C (zh) * 2002-11-20 2007-05-09 中国人民解放军军事医学科学院放射与辐射医学研究所 基质金属蛋白酶2的小肽抑制剂
EP1594550A4 (de) * 2003-01-24 2007-07-11 Barnes Jewish Hospital Chelatbildner mit lipophilen trägern
FI115035B (fi) * 2003-05-02 2005-02-28 Ctt Cancer Targeting Tech Oy In vivo -kuvantaminen käyttäen peptidijohdannaisia
FI20031528A0 (fi) * 2003-10-17 2003-10-17 Ctt Cancer Targeting Tech Oy Terapeuttinen liposomikoostumus ja menetelmä sen valmistamiseksi
FI20040572A0 (fi) * 2004-04-23 2004-04-23 Ctt Cancer Targeting Tech Oy Matriisi-metalloproteinaasin aktiviteetin inhibiittorit
FI20040682A0 (fi) * 2004-05-14 2004-05-14 Ctt Cancer Targeting Tech Oy Tuumorien ja mestastaasien kuvantaminen käyttäen gelatinaasiin targetoituvaa peptidiä
FR2870741B1 (fr) 2004-05-25 2008-03-14 Coletica Sa Phase lamellaires hydratees ou liposomes, contenant une monoamine grasse ou un polymere cationique favorisant la penetration intercellulaire, et composition cosmetique ou pharmaceutique la contenant.
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
CN101616692B (zh) * 2006-07-06 2013-05-08 纽约市哥伦比亚大学信托人 用于血管造影术的多色的不同大小的颗粒
CN102114000B (zh) * 2009-12-31 2013-08-21 复旦大学 一种载药的共输送脂质纳米递药系统
US8871189B2 (en) * 2011-11-30 2014-10-28 Mallinckrodt Llc MMP-targeted therapeutic and/or diagnostic nanocarriers
US11339209B2 (en) 2016-11-14 2022-05-24 Novartis Ag Compositions, methods, and therapeutic uses related to fusogenic protein minion

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5158760A (en) * 1990-05-30 1992-10-27 Board Of Regents, The University Of Texas System 99m TC labeled liposomes
IL130823A (en) * 1996-10-15 2005-12-18 Elan Pharm Inc Peptide-lipid conjugates, liposomes drug delivery
FI980604A0 (fi) * 1998-03-18 1998-03-18 Univ Helsinki Licensing Nya matrismetalloproteinasinhibitorer och -regulatorer

Also Published As

Publication number Publication date
NO20034280L (no) 2003-11-25
WO2002076491A1 (en) 2002-10-03
CA2441227A1 (en) 2002-10-03
DK1372694T3 (da) 2006-10-30
US20040213833A1 (en) 2004-10-28
FI113840B (fi) 2004-06-30
ES2266458T3 (es) 2007-03-01
CZ20032805A3 (cs) 2004-06-16
EP1372694B1 (de) 2006-06-28
US20050271588A1 (en) 2005-12-08
ATE331526T1 (de) 2006-07-15
DE60212814T2 (de) 2007-02-08
CN1250279C (zh) 2006-04-12
EE200300467A (et) 2003-12-15
KR20040000414A (ko) 2004-01-03
NZ528043A (en) 2005-08-26
CN1531439A (zh) 2004-09-22
EP1372694A1 (de) 2004-01-02
BR0208681A (pt) 2004-03-30
HUP0303649A2 (hu) 2004-01-28
FI20010620A0 (fi) 2001-03-26
PL365248A1 (en) 2004-12-27
IL158114A0 (en) 2004-03-28
RU2003131332A (ru) 2005-04-10
JP2004529127A (ja) 2004-09-24
HUP0303649A3 (en) 2005-12-28
SK12982003A3 (sk) 2004-08-03
NO20034280D0 (no) 2003-09-25
FI20010620A (fi) 2002-09-27
YU74703A (sh) 2006-05-25

Similar Documents

Publication Publication Date Title
DE60212814D1 (de) Liposomen-targeting von matrix-metalloproteinase-hemmern
WO2003002595A3 (en) Dipeptidyl peptidase iv inhibitors and their uses as anti-cancer agents
ATE475411T1 (de) Liposomenladung mit metallionen
WO2003009814A3 (en) Novel genes, compositions, kits, and methods for identification, assessment, prevention, and therapy of prostate cancer
NO20032069D0 (no) SN-38 lipid komplekser og fremgangsmåte for anvendelse derav
WO2002078639A3 (en) A method of treating proliferative diseases using eg5 inhibitors
EA200300934A1 (ru) Агенты и способы, предназначенные для лечения опухолевых заболеваний
RS52668B (en) ANTITUMOR EFFECT, ANTI-TUMOR AND ANALYSIS PROCESS
WO2001097855A3 (en) Targeted combination immunotherapy of cancer and infectious diseases
WO2005053725A3 (en) Cancer treatment
WO2003106640A3 (en) CELL TARGETING METHODS AND COMPOSITIONS
SE0100684D0 (sv) New subject-matter
HK1074840A1 (en) Novel dithiolopyrrolones with therapeutic activity
WO2005030225A3 (en) Method of inhibiting the expression of a multi-drug resistance genes and inhibiting the production of proteins resulting from the expression of such genes thereby enhancing the effectiveness of chemotherapeutic agents to treat cancers
WO2002074756A3 (de) Urokinase-inhibitoren
WO2003053999A3 (de) Selektive arylguanidinpeptide als urokinaseinhibitoren
WO2004052282A3 (en) Diterpenoid compounds, compositions thereof and their use as anti-cancer or anti-fungal agents
WO2002101076A3 (en) Methods for targeted expression of therapeutic nucleic acid
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
ATE391777T1 (de) Verwendung von prohibitin-rns in krebsbehandlung
DE60135743D1 (de) Liposomale einkapselung von alphastrahlern, und deren verwendung
GB2431656A (en) HAI-1 and HAI-2 in cancer therapy
WO2005003776A3 (en) In vitro methods for detecting renal cancer
WO2006020557A3 (en) Methods of using or identifying agents that inhibit cancer growth
WO2002056753A3 (en) P27 prevents cellular migration

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee